Search Results for: US Stem Cell

Answering reader questions: snorting stem cells, Regenexx, exosomes

Brain-PET-scan, stem cells

One of the most interesting parts of running The Niche is that I get all these questions about stem cells and related matters from readers. I try to answer questions regularly by email, but sometimes the volume catches up with me. For that reason I periodically try to do posts answering such questions, which has […]

Answering reader questions: snorting stem cells, Regenexx, exosomes Read More »

Recommended reads: secrets of cells, T-cells, CRISPR

cryo-ET

What are your favorite cells? The stem variety? T-cells? I have a hard time choosing just one favorite. The first news item I feature talks new imaging methods to see deep inside any cells. Have a favorite organelle? The secret lives of cells — as never seen before, Nature. This news item covers newer imaging techniques

Recommended reads: secrets of cells, T-cells, CRISPR Read More »

Clade Therapeutics pursues universal cells for cancer therapy

Chad-Cowan CRISPR Therapeutics

Clade  Therapeutics has been pursuing the idea of using gene-editing to make universally compatible cells. The potential here is big. What if you could make cloaked stem cells that could be used to produce cellular therapies that could be given to most patients without fear of immune rejection? Clade Therapeutics Boston Business Journal covers the

Clade Therapeutics pursues universal cells for cancer therapy Read More »

Weekly stem cell reads: pending FDA verdict, blood vessels, RA

Cellular populations in the vascular wall, stem cell niche

Any day now we should get the verdict from the judge in the big stem cell clinic case here in California against Cell Surgical Network, et al. It seems that the FDA is waiting on this verdict before taking some major actions. If the judge rules against the agency it could throw the area into

Weekly stem cell reads: pending FDA verdict, blood vessels, RA Read More »

Vertex upbeat on 1st stem cell therapy for diabetes trial participant

“While still early, these results support the continued progression of our VX-880 clinical studies, as well as future studies using our encapsulated islet cells, which hold the potential to be used without the need for immunosuppression,” said Bastiano Sanna, Ph.D., executive vice president and chief of cell and genetic therapies at Vertex.

It’s hard in the cell therapy field not to get excited even with bits of seemingly encouraging news but with N=1 reports we have to be very cautious and that’s the case with news from Vertex on their 1st stem cell therapy for diabetes trial participant. Vertex stem cell therapy for diabetes VX-880: N=1 This

Vertex upbeat on 1st stem cell therapy for diabetes trial participant Read More »